Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
NEW ORLEANS, May 04, 2018 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 19, 2018 to file lead plaintiff applications in a securities class action lawsuit against Myriad Genetics, Inc. (Nasdaq:MYGN), if they purchased the Company’s securities between August 13, 2014 through March 12, 2018, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Utah.
Get Help
Myriad investors should visit us at https://www.claimsfiler.com/cases/view-myriad-genetics-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
Myriad Genetics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On March 12, 2018, the Company revealed that it received a subpoena from the Department of Health and Human Services, regarding “an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid,” specifically relating to the Company’s hereditary cancer testing dating back to January 1, 2014 (less than four months after the Company launched its myRisk test in September 2013) to the date of the subpoena’s issuance.
On this news, the price of Myriad’s shares plummeted over 12.14%
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
